Evidence map›Paper›PMID 42308527›Full record

ArticleThe Journal of infectious diseases2026

Identification of Host Gene Transcripts by Machine Learning and Their Application to Predict Outcome in Ebola Virus Disease.

Jocelyn G Pérez, Natasha Y Rickett, Stephan Günther, Romy Kerber, Lisa F P Ng, Tom Fletcher, Tracy MacGill, Todd Myers, Robert Orr, Miles W Carroll and 2 more

Abstract read
In one paragraph

Article in The Journal of infectious diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Jocelyn G PérezSchool of Biodiversity, One Health and Veterinary Medicine, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, United Kingdom.ORCID 0000-0002-4887-2786
Natasha Y RickettInstitute of Infection, Veterinary and Ecological Science, Faculty of Health and Life Science, University of Liverpool, Liverpool, United Kingdom.ORCID 0000-0002-3172-1877
Stephan GüntherBernhard Nocht Institute for Tropical Medicine, Hamburg, Germany.ORCID 0000-0002-6562-0230
Romy KerberBernhard Nocht Institute for Tropical Medicine, Hamburg, Germany.ORCID 0000-0001-8152-8189
Lisa F P NgA*STAR Infectious Diseases Labs, Singapore.
Tom FletcherLiverpool School of Tropical Medicine, Liverpool, United Kingdom.ORCID 0000-0002-3712-415X
Tracy MacGillOffice of Regulatory and Emerging Science, Food and Drug Administration, Silver Spring, Maryland, USA.ORCID 0009-0007-9092-2680
Todd MyersOffice of Regulatory and Emerging Science, Food and Drug Administration, Silver Spring, Maryland, USA.
Robert OrrOffice of Regulatory and Emerging Science, Food and Drug Administration, Silver Spring, Maryland, USA.
Miles W CarrollWellcome Centre for Human Genetics, Nuffield Department of Medicine, Oxford University, Oxford, United Kingdom.
Neil BlakeInstitute of Infection, Veterinary and Ecological Science, Faculty of Health and Life Science, University of Liverpool, Liverpool, United Kingdom.
Julian A HiscoxInstitute of Infection, Veterinary and Ecological Science, Faculty of Health and Life Science, University of Liverpool, Liverpool, United Kingdom.ORCID 0000-0002-6582-0275

Funding

Consejo Nacional de Ciencia, Tecnología e Innovación 100-2016-FONDECYTFondo Nacional de Desarrollo Científico, Tecnológico y de Innovación TecnológicaPandemic InstituteUS Food and Drug Administration HHSF223201510104CUS Food and Drug Administration HHSF223201710194C
6 · The paper itself

Abstract

backgroundIn humans, Ebola virus disease (EVD) has a high mortality rate. While viral load is a known prognostic factor, it is not effective in predicting outcomes across all patients. Exploring host transcriptomic signatures may provide additional predictive value.

methodsHere, the transcript abundance of 4 candidate host genes (VCAM1, TUBG1, MS4A4A, ISG15) was quantified by reverse transcription quantitative polymerase chain reaction (RT-qPCR) in blood samples from hospitalized patients with Ebola virus (EBOV) collected during the 2013-2016 West African outbreak. Samples were taken for diagnostic purposes during the acute phase of infection. Associations between target gene expression, viral load, and outcome (survival/death) were assessed, and machine learning models were trained and tested to predict patient outcome.

resultsEBOV cycle threshold (Ct) values were significantly higher in hospitalized survivors compared to fatalities. During the acute phase, the transcript abundance of VCAM1 and MS4A4A was higher in fatal cases, while TUBG1 expression was elevated in survivors; ISG15 expression did not differ by outcome. In support vector machine models, EBOV Ct alone classified patient outcomes with 86.9% accuracy, while MS4A4A alone reached 82.6%. Combining EBOV Ct with MS4A4A improved prediction to 91.3%. The best-performing model, integrating EBOV Ct, ISG15, and MS4A4A, achieved 100% accuracy in the test set. DISCUSSION: Host gene expression markers, particularly MS4A4A, in combination with viral load, improved outcome prediction in EVD beyond viral load alone in ambiguous cases with mid-range Ct values. These findings highlight the utility of host transcript-based assays to inform clinical management and for benchmarking the effectiveness of medical countermeasures during outbreaks.

Indexed as

EbolavirusHemorrhagic Fever, EbolaMachine LearningAdultAfrica, WesternDisease OutbreaksFemaleGene Expression ProfilingHumansMalePredictive Learning ModelsPrognosisTranscriptomeViral LoadEbola virusEbola virus diseaseEBOVEVDmachine learningmedical countermeasuretranscriptome

Identifiers

PMID42308527
PMCPMC13668333

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.